盐酸阿罗洛尔对非卧床持续性腹膜透析高血压疗效观察

目的研究盐酸阿罗洛尔对非卧床持续性腹膜透析（CAPD）高血压患者的降压疗效。方法选择CAPD高血压患者38例，分为治疗组（20例）与对照组（18例）。治疗组给予口服盐酸阿罗洛尔10mg／次，每天1次，共治疗4周。观察治疗前后血压、心率及胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、载脂蛋白Al（Apo-Al）、载脂蛋白B（Apo-B）的变化。对照组患者维持原治疗方案不变，分别于实验前后检测相应指标。结果4周后，治疗组患者血压、心率明显下降，与治疗前及对照组比较均有显著差异（P〈0．01）；治疗组患者治疗前后TC、TG、HDL、LDL、Apo—Al、Apo—B无显著变化（P〉0．05）。结论盐酸阿罗洛尔对CAPD高血压患者有治疗效果，同时短期内不影响CAPD患者脂质代谢。

Effectiveness of arotinolol in treating obstinate hypertension and lipid metabolic disorder in continuous ambulatory peritoneal dialysis patients

Objective To study the effectiveness of arotinolol in treating obstinate nypertension and lipid metabolic disorder in continuous ambulatory peritoneal dialysis（CAPD） patients. Method Thirty-eight CAPD patients with obstinate hypertension were randomly divided into treatment group （n = 20） and control group （n = 18）. The patients in treatment group were treated with daily doses of 10 mg arotinolol for 4 weeks, and the ambulatory blood pressure, heart rate, cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B were monitored before and after the treatment. Result After 4 weeks in treatment group the mean blood pressure and heart rate were decreased obv）ously, btt there was no significant changes in cholesterol, triglyceride, high-density-lipoprotein, low-density-lipoprotein, apolipoprotein-Al, apolipoprotein-B. Conclusion Arotinolol is effective in treating obstinate hypertensio, associated with CAPD and can not aggravate lipid metabolic disorder in a short period.